Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.81 and traded as high as $2.81. Microbot Medical shares last traded at $2.81, with a volume of 1,158,755 shares changing hands.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Microbot Medical in a report on Thursday, April 10th.
View Our Latest Report on Microbot Medical
Microbot Medical Stock Up 4.4%
The firm has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $1.83. The stock has a market capitalization of $94.58 million, a P/E ratio of -3.25 and a beta of 1.14.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. On average, research analysts predict that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Investors Weigh In On Microbot Medical
Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in Microbot Medical during the 1st quarter worth approximately $57,000. Virtu Financial LLC acquired a new stake in shares of Microbot Medical during the first quarter valued at about $42,000. Renaissance Technologies LLC bought a new stake in shares of Microbot Medical during the fourth quarter worth about $118,000. Finally, Geode Capital Management LLC grew its holdings in Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares during the last quarter. 16.30% of the stock is currently owned by institutional investors and hedge funds.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
